Data Indicate Prostate Cancer Screening Saves Lives.

Medscape (4/24, Johnson) reports, “For the first time, updated results from the European Randomized Study of Screening for Prostate Cancer (ERSPC), the largest randomized prostate cancer screening trial in the world, show a significant survival advantage with prostate-specific antigen (PSA) screening for men from 50 to 74 years of age.” These findings “come from a follow-up of 13 years, and were presented during a late-breaking abstract session…at the European Association of Urology 29th Annual Congress.” Medscape points out that “an initial analysis of the ERSPC results, reported in 2009, provided the first proof that PSA screening saves lives from prostate cancer.”